PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing

被引:33
作者
Bai, Xusheng [1 ]
Zhang, Enke [1 ]
Ye, Hua [2 ]
Nandakumar, Vijayalakshmi
Wang, Zhuo [1 ]
Chen, Lihong [1 ]
Tang, Chuanning [2 ]
Li, Jianhui [1 ]
Li, Huijin [1 ]
Zhang, Wei [1 ]
Han, Wei [1 ]
Lou, Feng [2 ]
Zhang, Dandan [2 ]
Sun, Hong [2 ]
Dong, Haichao [2 ]
Zhang, Guangchun [2 ]
Liu, Zhiyuan [2 ]
Dong, Zhishou [2 ]
Guo, Baishuai [2 ]
Yan, He [2 ]
Yan, Chaowei [2 ]
Wang, Lu [2 ]
Su, Ziyi [2 ]
Li, Yangyang [2 ]
Jones, Lindsey [3 ]
Huang, Xue F. [3 ]
Chen, Si-Yi [3 ]
Gao, Jinglong [1 ]
机构
[1] Peoples Hosp Shan Xi Prov, Cent Lab, Xian, Peoples R China
[2] San Valley Biotechnol Inc, Beijing, Peoples R China
[3] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA
来源
PLOS ONE | 2014年 / 9卷 / 06期
基金
中国国家自然科学基金;
关键词
KINASE INHIBITORS; OVARIAN-CANCER; PREVENTION; EXPRESSION; LAPATINIB; HER2; P53; REDUCTION; EFFICACY; RECEPTOR;
D O I
10.1371/journal.pone.0099306
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Breast cancer is the most common malignancy and the leading cause of cancer deaths in women worldwide. While specific genetic mutations have been linked to 5-10% of breast cancer cases, other environmental and epigenetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive breast cancer molecular profile is needed to develop more effective target therapies. Until recently, identifying genetic cancer mutations via personalized DNA sequencing was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 105 human breast cancer samples. The sequencing analysis revealed missense mutations in PIK3CA, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.
引用
收藏
页数:9
相关论文
共 40 条
[1]  
Alsner J, 2000, CLIN CANCER RES, V6, P3923
[2]  
[Anonymous], 2013, GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base
[3]   Cancer-specific mutations in PIK3CA are oncogenic in vivo [J].
Bader, AG ;
Kang, SY ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1475-1479
[4]   Combining Highly Multiplexed PCR with Semiconductor-Based Sequencing for Rapid Cancer Genotyping [J].
Beadling, Carol ;
Neff, Tanaya L. ;
Heinrich, Michael C. ;
Rhodes, Katherine ;
Thornton, Michael ;
Leamon, John ;
Andersen, Mark ;
Corless, Christopher L. .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (02) :171-176
[5]   A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].
Berns, Katrien ;
Horlings, Hugo M. ;
Hennessy, Bryan T. ;
Madiredjo, Mandy ;
Hijmans, E. Marielle ;
Beelen, Karin ;
Linn, Sabine C. ;
Gonzalez-Angulo, Ana Maria ;
Stemke-Hale, Katherine ;
Hauptmann, Michael ;
Beijersbergen, Roderick L. ;
Mills, Gordon B. ;
de Vijver, Marc J. van ;
Bernards, Rene .
CANCER CELL, 2007, 12 (04) :395-402
[6]  
Bertucci Francois, 2008, J Biol, V7, P6, DOI 10.1186/jbiol67
[7]   Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS) [J].
Blackburn, George L. ;
Wang, Katherine A. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 86 (03) :878S-881S
[8]   Environmental pollutants, diet, physical activity, body size, and breast cancer - Where do we stand in research to identify opportunities for prevention? [J].
Brody, Julia Green ;
Rudel, Ruthann A. ;
Michels, Karin B. ;
Moysich, Kirsten B. ;
Bernstein, Leslie ;
Attfield, Kathleen R. ;
Gray, Sharon .
CANCER, 2007, 109 (12) :2627-2634
[9]   Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial [J].
Cauley, JA ;
Norton, L ;
Lippman, ME ;
Eckert, S ;
Krueger, KA ;
Purdie, DW ;
Farrerons, J ;
Karasik, A ;
Mellstrom, D ;
Ng, KW ;
Stepan, JJ ;
Powles, TJ ;
Morrow, M ;
Costa, A ;
Silfen, SL ;
Walls, EL ;
Schmitt, H ;
Muchmore, DB ;
Jordan, VC .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 65 (02) :125-134
[10]   Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer [J].
Chen, Wendy Y. ;
Colditz, Graham A. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (07) :415-423